<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35448890</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2072-6651</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Toxins</Title>
          <ISOAbbreviation>Toxins (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High Cell Density Cultivation Process for the Expression of Botulinum Neurotoxin a Receptor Binding Domain.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">281</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/toxins14040281</ELocationID>
        <Abstract>
          <AbstractText>The receptor-binding domain of botulinum neurotoxin (H<sub>C</sub> fragment), is a promising botulism vaccine candidate. In the current study, fermentation strategies were evaluated to upscale H<sub>C</sub> fragment expression. A simple translation of the growth conditions from shake flasks to a batch fermentation process resulted in limited culture growth and protein expression (OD of 11 and volumetric protein yields of 123 mg/L). Conducting fed-batch fermentation with rich media and continuous nutrient supplementation significantly improved culture growth (OD of 40.3) and protein expression (1093 mg/L). A further increase in H<sub>C</sub> fragment yield was achieved by high cell density cultivation (HCDC). The bacterium was grown in a defined medium and with a combined bolus/continuous feed of nutrients to maintain desired oxygen levels and prevent acetate accumulation. The final OD of the process was 260, and the volumetric yield of the H<sub>C</sub> fragment was 2065 mg/L, which reflects improvement by an order of magnitude. Purified H<sub>C</sub> fragments, produced by HCDC, exhibited typical biochemical and protective characteristics in mice. Taken together, the advancements achieved in this study promote large-scale production of the H<sub>C</sub> fragment in <i>E. coli</i> for use in anti-botulism vaccines.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ben David</LastName>
            <ForeName>Alon</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papir</LastName>
            <ForeName>Yoel</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hazan</LastName>
            <ForeName>Ophir</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Redelman</LastName>
            <ForeName>Moses</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diamant</LastName>
            <ForeName>Eran</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barnea</LastName>
            <ForeName>Ada</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Torgeman</LastName>
            <ForeName>Amram</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zichel</LastName>
            <ForeName>Ran</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-3249-4901</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Toxins (Basel)</MedlineTA>
        <NlmUniqueID>101530765</NlmUniqueID>
        <ISSNLinking>2072-6651</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003470">Culture Media</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.69</RegistryNumber>
          <NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019274" MajorTopicYN="Y">Botulinum Toxins, Type A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001906" MajorTopicYN="Y">Botulism</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003470" MajorTopicYN="N">Culture Media</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Clostridium botulinum</Keyword>
        <Keyword MajorTopicYN="N">fermentation</Keyword>
        <Keyword MajorTopicYN="N">high cell density cultivation</Keyword>
        <Keyword MajorTopicYN="N">recombinant protein expression</Keyword>
        <Keyword MajorTopicYN="N">subunit vaccine</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>20</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35448890</ArticleId>
        <ArticleId IdType="pmc">PMC9031141</ArticleId>
        <ArticleId IdType="doi">10.3390/toxins14040281</ArticleId>
        <ArticleId IdType="pii">toxins14040281</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gill D.M. Bacterial toxins: A table of lethal amounts. Microbiol. Rev. 1982;46:86–94. doi: 10.1128/mr.46.1.86-94.1982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mr.46.1.86-94.1982</ArticleId>
            <ArticleId IdType="pmc">PMC373212</ArticleId>
            <ArticleId IdType="pubmed">6806598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: Past, present, and future. Crit. Rev. Immunol. 2007;27:303–318. doi: 10.1615/CritRevImmunol.v27.i4.20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1615/CritRevImmunol.v27.i4.20</ArticleId>
            <ArticleId IdType="pubmed">18197811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montal M. Botulinum neurotoxin a marvell of protein design. Annu. Rev. Biochem. 2010;79:591–617. doi: 10.1146/annurev.biochem.051908.125345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.051908.125345</ArticleId>
            <ArticleId IdType="pubmed">20233039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rusnak J.M., Smith L.A. Botulinum neurotoxin vaccines: Past history and recent developments. Hum. Vaccines. 2009;5:794–805. doi: 10.4161/hv.9420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/hv.9420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., et al.  Botulinum toxin as a biological weapon: Medical and public health managment. J. Am. Med Assoc. 2001;285:1059–1070. doi: 10.1001/jama.285.8.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.285.8.1059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith L.A. Development of recombinant vaccines for botulinum neurotoxin. Toxicon. 1998;36:1539–1548. doi: 10.1016/S0041-0101(98)00146-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0041-0101(98)00146-9</ArticleId>
            <ArticleId IdType="pubmed">9792170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith L.A. Botulism and vaccines for its prevention. Vaccine. 2009;27:D33–D39. doi: 10.1016/j.vaccine.2009.08.059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2009.08.059</ArticleId>
            <ArticleId IdType="pubmed">19837283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasetti-Escargueil C., Popoff M.R. Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins. 2020;13:1.  doi: 10.3390/toxins13010001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13010001</ArticleId>
            <ArticleId IdType="pmc">PMC7821915</ArticleId>
            <ArticleId IdType="pubmed">33374954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shone C., Agostini H., Clancy J., Gu M., Yang H.H., Chu Y., Johnson V., Taal M., McGlashan J., Brehm J., et al.  Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect. Immun. 2009;77:2795–2801. doi: 10.1128/IAI.01252-08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01252-08</ArticleId>
            <ArticleId IdType="pmc">PMC2708551</ArticleId>
            <ArticleId IdType="pubmed">19398544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webb R.P., Smith T.J., Smith L.A., Wright P.M., Guernieri R.L., Brown J.L., Skerry J.C. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins. 2017;9:269.  doi: 10.3390/toxins9090269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins9090269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zichel R., Mimran A., Keren A., Barnea A., Steinberger-Levy I., Marcus D., Turgeman A., Reuveny S. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin. Vaccine Immunol. 2010;17:784–792. doi: 10.1128/CVI.00496-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00496-09</ArticleId>
            <ArticleId IdType="pmc">PMC2863383</ArticleId>
            <ArticleId IdType="pubmed">20357058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiyatkin N., Maksymowych A.B., Simpson L.L. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 1997;65:4586–4591. doi: 10.1128/iai.65.11.4586-4591.1997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.65.11.4586-4591.1997</ArticleId>
            <ArticleId IdType="pmc">PMC175658</ArticleId>
            <ArticleId IdType="pubmed">9353037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shearer J.D., Vassar M.L., Swiderski W., Metcalfe K., Niemuth N., Henderson I. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B) Vaccine. 2010;28:7313–7318. doi: 10.1016/j.vaccine.2010.08.076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.08.076</ArticleId>
            <ArticleId IdType="pubmed">20816903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khouri J.M., Motter R.N., Arnon S.S. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Vaccine. 2018;36:2041–2048. doi: 10.1016/j.vaccine.2018.02.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.02.042</ArticleId>
            <ArticleId IdType="pubmed">29475762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., Barbieri J.T. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 2008;76:1314–1318. doi: 10.1128/IAI.01025-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01025-07</ArticleId>
            <ArticleId IdType="pmc">PMC2258812</ArticleId>
            <ArticleId IdType="pubmed">18070903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 1995;63:2738–2742. doi: 10.1128/iai.63.7.2738-2742.1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.63.7.2738-2742.1995</ArticleId>
            <ArticleId IdType="pmc">PMC173366</ArticleId>
            <ArticleId IdType="pubmed">7790092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaPenotiere H.F., Clayton M.A., Middlebrook J.L. Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon. 1995;33:1383–1386. doi: 10.1016/0041-0101(95)00072-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0041-0101(95)00072-T</ArticleId>
            <ArticleId IdType="pubmed">8599190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boles J., West M., Montgomery V., Tammariello R., Pitt M.L.M., Gibbs P., Smith L., LeClaire R.D. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon. 2006;47:877–884. doi: 10.1016/j.toxicon.2006.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2006.02.013</ArticleId>
            <ArticleId IdType="pubmed">16730042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 1998;66:4817–4822. doi: 10.1128/IAI.66.10.4817-4822.1998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.66.10.4817-4822.1998</ArticleId>
            <ArticleId IdType="pmc">PMC108595</ArticleId>
            <ArticleId IdType="pubmed">9746584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrne M.P., Titball R.W., Holley J., Smith L.A. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr. Purif. 2000;18:327–337. doi: 10.1006/prep.2000.1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/prep.2000.1200</ArticleId>
            <ArticleId IdType="pubmed">10733887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dux M.P., Barent R., Sinha J., Gouthro M., Swanson T., Barthuli A., Inan M., Ross J.T., Smith L.A., Smith T.J., et al.  Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115. Protein Expr. Purif. 2006;45:359–367. doi: 10.1016/j.pep.2005.08.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pep.2005.08.015</ArticleId>
            <ArticleId IdType="pubmed">16214371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dux M.P., Huang J., Barent R., Inan M., Swanson S.T., Sinha J., Ross J.T., Smith L.A., Smith T.J., Henderson I., et al.  Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(Hc)] expressed in Pichia pastoris. Protein Expr. Purif. 2011;75:177–185. doi: 10.1016/j.pep.2010.09.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pep.2010.09.016</ArticleId>
            <ArticleId IdType="pubmed">20933089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter K.J., Zhang W., Smith L.A., Meagher M.M. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr. Purif. 2000;19:393–402. doi: 10.1006/prep.2000.1256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/prep.2000.1256</ArticleId>
            <ArticleId IdType="pubmed">10910730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben David A., Diamant E., Barnea A., Rosen O., Torgeman A., Zichel R. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo. Clin. Vaccine Immunol. 2013;20:1266–1273. doi: 10.1128/CVI.00268-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00268-13</ArticleId>
            <ArticleId IdType="pmc">PMC3754506</ArticleId>
            <ArticleId IdType="pubmed">23761665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiloach J., Fass R. Growing E. coli to high cell density—A historical perspective on method development. Biotechnol. Adv. 2005;23:345–357. doi: 10.1016/j.biotechadv.2005.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biotechadv.2005.04.004</ArticleId>
            <ArticleId IdType="pubmed">15899573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zha D., Linden T., Potgieter T.  Production of monoclonal antibodies in glycoengineered Pchia pastoris. In: Al-Rubeai, editor. Antibody Expression and Production. Springer; Dordrecht, The Netherlands: Heidelberg, Germany: London, UK: New York, NY, USA: 2011. pp. 77–98.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang D.L.C., Cooney C.L., Demain A.L., Dunnill P., Humphrey A.E., Lilley M.D.  Fermentation and Enzyme Technology. John Wiley &amp; Sons Ltd.; New York, NY, USA: 1979. </Citation>
        </Reference>
        <Reference>
          <Citation>Ko Y.F., Bentley W.E., Weigand W.A. The effect of cellular energetics on foreign protein production. Appl. Biochem. Biotechnol. 1995;50:145–159. doi: 10.1007/BF02783451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02783451</ArticleId>
            <ArticleId IdType="pubmed">7717707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han K., Lim H.C., Hong J. Acetic acid formation in Escherichia coli fermentation. Biotechnol. Bioeng. 1992;39:663–671. doi: 10.1002/bit.260390611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bit.260390611</ArticleId>
            <ArticleId IdType="pubmed">18600996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleman G.L., Strohl W.R. Acetate metabolism by Escherichia coli in high-cell-density fermentation. Appl. Environ. Microbiol. 1994;60:3952–3958. doi: 10.1128/aem.60.11.3952-3958.1994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aem.60.11.3952-3958.1994</ArticleId>
            <ArticleId IdType="pmc">PMC201921</ArticleId>
            <ArticleId IdType="pubmed">7993084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doelle H.W., Ewings K.N., Hollywood N.W.  Microbial Reactions. Springer; Berlin/Heidelberg, Germany: 1982. Regulation of glucose metabolism in bacterial systems; pp. 1–35.</Citation>
        </Reference>
        <Reference>
          <Citation>Korz D.J., Rinas U., Hellmuth K., Sanders E.A., Deckwer W.D. Simple fed-batch technique for high cell density cultivation of Escherichhia coli. J. Biotechnol. 1995;39:59–65. doi: 10.1016/0168-1656(94)00143-Z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0168-1656(94)00143-Z</ArticleId>
            <ArticleId IdType="pubmed">7766011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer H.-P., Leist C., Fiechter A. Acetate formation in continuous culture of Escherichia coli K12 D1 on defined and complex media. J. Biotechnol. 1984;1:355–358. doi: 10.1016/0168-1656(84)90027-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0168-1656(84)90027-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grossman T.H., Kawasaki E.S., Sandhya R.P., Osburne M.S. Spontaneous cAMP-dependent derepression of gene expression in stationary phase plays a role in recombinant expression instability. Gene. 1998;209:95–103. doi: 10.1016/S0378-1119(98)00020-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0378-1119(98)00020-1</ArticleId>
            <ArticleId IdType="pubmed">9524234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavallaei M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., Raffestin S., Popoff M., Marvaud J.C. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antivodies. FEBS Letters. 2004;572:299–306. doi: 10.1016/j.febslet.2004.06.094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2004.06.094</ArticleId>
            <ArticleId IdType="pubmed">15304366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 2005;73:6998–7005. doi: 10.1128/IAI.73.10.6998-7005.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.73.10.6998-7005.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1230911</ArticleId>
            <ArticleId IdType="pubmed">16177380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi J.H., Keum K.C., Lee S.Y. Production of recombinant proteins by high cell density culture of Escherichia coli. Chem. Eng. Sci. 2006;61:876–885. doi: 10.1016/j.ces.2005.03.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ces.2005.03.031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong K.J., Lee S.Y. High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification. Appl. Environ. Microbiol. 1999;65:3027–3032. doi: 10.1128/AEM.65.7.3027-3032.1999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AEM.65.7.3027-3032.1999</ArticleId>
            <ArticleId IdType="pmc">PMC91452</ArticleId>
            <ArticleId IdType="pubmed">10388699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glazyrina J., Materne E.M., Dreher T., Storm D., Junne S., Adams T., Greller G., Neubauer P. High cell density cultivation and recombinant protein production with Escherichia coli in a rocking-motion-type bioreactor. Microb. Cell Fact. 2010;9:42. doi: 10.1186/1475-2859-9-42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1475-2859-9-42</ArticleId>
            <ArticleId IdType="pmc">PMC2891675</ArticleId>
            <ArticleId IdType="pubmed">20509968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roos N., Breiner B., Preuss L., Lilie H., Hipp K., Herrmann H., Horn T., Biener R., Iftner T., Simon C. Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E. coli. Protein Expr. Purif. 2020;175:105690. doi: 10.1016/j.pep.2020.105690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pep.2020.105690</ArticleId>
            <ArticleId IdType="pubmed">32681956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diamant E., Lachmi B.E., Keren A., Barnea A., Marcus H., Cohen S., Ben David A., Zichel R. Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS ONE. 2014;9:e87089.  doi: 10.1371/journal.pone.0087089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0087089</ArticleId>
            <ArticleId IdType="pmc">PMC3903612</ArticleId>
            <ArticleId IdType="pubmed">24475231</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
